| FEIGERLOVA, Eva |
NCT05473091: Is There a Link Between Inflammation and Endocrinopathies in Turner Syndrome? |
|
|
| Completed | N/A | 179 | Europe | no intervention | Central Hospital, Nancy, France | Turner Syndrome | 03/22 | 09/22 | | |
NCT05474768: Expectations and Beliefs of Transgender People Regarding Hormonal Treatment |
|
|
| Recruiting | N/A | 20 | Europe | no intervention | Central Hospital, Nancy, France | Transgenderism | 11/22 | 01/23 | | |
| BRONOWICKI, Jean-Pierre |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Active, not recruiting | 2b | 357 | Europe, Canada, US, RoW | belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo | Galectin Therapeutics Inc., Galectin Therapeutics Inc | Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis | 12/24 | 12/24 | | |
LEGEND, NCT05232071: Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus |
|
|
| Completed | 2 | 42 | Europe, US | IVA337, Lanifibranor, Placebo, Empagliflozin, Jardiance | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2 | 03/24 | 06/24 | | |
IP-CURE-B, NCT05045261: ANRS HB07 IP-Cure-B Proof of Concept (PoC) Clinical Trial. Educating the Liver Immune Environment Through TLR8 Stimulation Followed by NUC Discontinuation |
|
|
| Recruiting | 2 | 100 | Europe | administration of SLGN in arm C, Discontinuation of NUC treatment in arms B and C | ANRS, Emerging Infectious Diseases, EUCLID Clinical Trial Platform | Hepatitis B, Chronic | 06/24 | 06/24 | | |
AB-LATE02, NCT04727307: Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial |
|
|
| Recruiting | 2 | 202 | Europe | Atezolizumab (neoadjuvant), Tecentriq, Percutaneous Radiofrequency, Bevacizumab (adjuvant), Avastin 400 mg in 16 ml Injection, Avastin 100 mg in 4 ml Injection, Atezolizumab (adjuvant) | University Hospital, Montpellier | Hepatocellular Carcinoma | 02/26 | 02/31 | | |
NCT03695796: French Cohort for the Study of Non-invasive Tests of Liver Lesions in NAFLD/NASH (FreSH Cohort) |
|
|
| Recruiting | N/A | 1000 | Europe | biopsy-proven NAFLD patients with non-invasive tests of liver fibrosis (blood tests, elastography devices) and biobank | University Hospital, Angers | NAFLD | 11/24 | 12/24 | | |
SEPT9-CROSS, NCT03311152: Circulating Cell-free DNA-based Epigenetic Biomarker MSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis |
|
|
| Completed | N/A | 529 | Europe | "Epi proColon 2.0 CE" test from Epigenomics, Inc (Berlin, Germany), Plasma mSEPT9 test | Central Hospital, Nancy, France, Institut National de la Santé Et de la Recherche Médicale, France, Groupement Interrégional de Recherche Clinique et d'Innovation, Epigenomics, Inc, New Day Diagnostics | Hepatocellular Carcinoma, Cirrhosis | 10/24 | 10/24 | | |
NCT05567328: Validation of the New Vibration-guided FibroScan Examination |
|
|
| Completed | N/A | 270 | Europe | Research FibroScan (FS) | Echosens | Liver Diseases | 12/24 | 12/24 | | |
| Recruiting | N/A | 502 | Europe | FIB4 | University Hospital, Angers | Screening, Advanced Liver Fibrosis | 01/25 | 01/25 | | |
